Comparison of model-generated estimates of HAART regimen ‘switching’ versus published data.

HAART  =  highly active antiretroviral therapy; WIHS  =  Women's Interagency HIV Study.
*Extracted from “Timing and Characteristics of Switching HAART Regimens in WIHS between 1994 and 2000” (Kirstein et al. JAIDS 2002).[34]
†Average of 50 best-fitting parameter sets weighted by CD4 cell distribution.
‡Lower bound of 20% represents proportion switching 1st line HAART due to virologic failure; upper bound of 45.25% represents proportion switching 2nd line HAART due to virologic failure plus an assumption that 25% of women with minor toxicity and all women with nonfatal major toxicity require a single drug switch. This estimate is based on data from Staszewski et al showing that of the 43% who discontinued indinavir plus two nucleoside reverse transcriptase inhibitors for any reason, 11% was due to symptoms such as gastrointestinal effects.[42]